Evecxia Therapeutics
View On Demand

Helping The 7 Million Depression Patients Prozac Doesn't

About the Event

Evecxia Therapeutics’ lead drug candidate EVX-101 is a potentially superior treatment for the millions of depression patients not treated adequately by standard antidepressants, e.g., Prozac®. Evecxia’s second drug candidate EVX-301 could become the first drug for patients hospitalized for suicidal ideation crisis and a critical tool in reducing lives lost to suicide. Both EVX‑101 and EVX-301 have successfully completed clinical safety trials (“Phase 1”) in healthy volunteers and are ready for proof-of-concept trials (“Phase 2”) in patients. The depression treatment market in 2022 was $12B and is projected to grow to $16B by 2030.

First-line antidepressants, e.g., Prozac®, work well in only one-third of patients. Current next-line antidepressants, e.g., Abilify®, provide only modest additional relief and are saddled with often serious side effects. Data suggest EVX-101 will be safer and more effective than Abilify®, addressing a market of 7 million patients in the U.S. alone. There are 1 million hospitalizations annually in the U.S. for suicidal ideation crisis – but no approved treatments.

Join this Fireside Chat with:

  • George Papakostas, MD: Director, Treatment-Resistant Depression Studies, Depression Clinical and Research Program, Massachusetts General Hospital, Professor of Psychiatry, Harvard Medical School
  • Jacob Jacobson: Founder and Chief Science Officer, Evecxia Therapeutics 

You’ll hear how EVX-101 and EVX-301 could enable many patients suffering from debilitating mood disorders to lead happier and fuller lives.

Sign Up Today


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.